The interim results at 24 weeks were as follows. Two patients in each arm discontinued due to adverse events. Indeed, the percentage of patients in each study arm who achieved viral undetectability is better than many studies of treatment-na ve patients. The maximal or peak concentration change was not reported. The drug levels of Sustiva in the current study were reported to be the same in both study arms.
Limitations are as follows.
It would have been helpful to see the rates of viral undetectability using an ultrasensitive test. The CD4 increase was modest, but will likely continue to increase among those who have persistently undetectable viral loads or who maintain lower levels than at baseline. It would be unfortunate if one or several of the cholesterol-lowering agents significantly reduced the lopinavir drug levels. Fichtenbaum C and others. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors.